Venture capitalists loosened their purse strings as we near the end of the decade, pouring over $624 million into 58 Boston-area startups.
Some notable funding rounds included Cambridge-based epigenetics company Constellation Pharmaceuticals‘ $65 million in equity, Watertown-based microbiome company Arranta Bio‘s $82 million funding round and Cambridge-based hematology company Disc Medicine‘s $50 million Series A.
Investors raised a significant sum of money in October as well. Sverica Capital Management, a growth-oriented, lower-middle-market private equity firm, closed its fifth private equity fund, Sverica Capital Partners V, at $450 million. Clean Energy Ventures closed its first fund at $110 million, which it will use to create a portfolio of 20 to 25 energy startups.
Catalyst Health Ventures raised $60.5 million for its fourth fund, which will target tech solutions in the health care and life science industries. And Seaport District biotechnology startup Ginkgo Bioworks raised a $350 million fund to more easily invest in spinout ventures that use its bioengineering technology in a variety of industries that are just starting to use cutting-edge biology.
Read Complete Article